# A Trial of the Safety and Efficacy of Single-Dose Administration of ANB-010 in Subjects With Hemophilia A

> **NCT06185335** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Biocad** · enrollment: 50 (estimated)

## Conditions studied

- Hemophilia A

## Interventions

- **GENETIC:** ANB-010, dose 1
- **GENETIC:** ANB-010, dose 2
- **GENETIC:** ANB-010, dose 3

## Key facts

- **NCT ID:** NCT06185335
- **Lead sponsor:** Biocad
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-07-26
- **Primary completion:** 2025-12
- **Final completion:** 2033-06
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06185335

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06185335, "A Trial of the Safety and Efficacy of Single-Dose Administration of ANB-010 in Subjects With Hemophilia A". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06185335. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*